Adagene(ADAG)
$1.71-0.29 (-14.50%)
ADAG
Adagene stock drug pipeline
$1.71
At close:-0.29 (-14.50%)
Want to see ADAG full AI Analyst Report?
Adagene (ADAG) Drug Pipeline
118 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Adagene, Inc. (ADAG) have in its pipeline
Adagene ADAG is currently developing the following drugs: Adg206, Pembrolizumab (Keytruda®), Adg126, Standard Of Care (Trifluridine/Tipiracil-Bevacizumab), Standard Of Care (Fruquintinib), Atezolizumab, Nkt2152, Adg126, Tocilizumab, Tpst-1120, Tiragolumab, Bevacizumab 10 Mg/Kg, Bevacizumab 15 Mg/Kg, Tobemstomig 2100 Mg, Tobemstomig 600 Mg, Tobemstomig 1200 Mg, Io-108 1800 Mg, Io-108 1200 Mg, Adg116, Adg106, Anti Pd1 Drug. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
